文献速递消化系统肿瘤

不同APC突变类型决定结直肠癌对端锚聚合酶抑制剂的反应

Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.
PubMed 文献 · Cancer Discov · 2019-07-23

该研究利用新动物模型、人细胞系和离体类器官培养,发现端锚聚合酶(TNKS)抑制可控制WNT过度激活并在体内实现长期肿瘤控制,但有效反应关键取决于APC基因的破坏方式。突变簇区域内截短的APC蛋白能与破坏复合体结合并抑制WNT转录程序,而早期截短(如Apc Min)与AXIN1和β-catenin相互作用有限,对TNKS阻断无反应。

要点

  • TNKS抑制可重建WNT/β-catenin信号的内源性控制。
  • APC突变位置决定TNKS抑制的疗效。
  • 早期截短APC(如Apc Min)对TNKS阻断无反应。

核心结论

  • TNKS抑制与APC恢复类似,可重建WNT/β-catenin信号的内源性控制,但APC基因型是反应的关键决定因素。

研究设计与样本

  • 研究使用新动物模型、人细胞系和离体类器官培养进行实验。

主要发现

  • TNKS抑制可控制WNT过度激活并在体内提供长期肿瘤控制,但有效反应关键取决于APC的破坏方式。
  • 突变簇区域内截短的APC蛋白能与破坏复合体结合并抑制WNT转录程序。
  • 早期截短的APC变体(如Apc Min)与AXIN1和β-catenin相互作用有限,且对TNKS阻断无反应。

关键数值与推荐

  • 突变簇区域内截短的APC蛋白能与破坏复合体结合并抑制WNT转录程序。
  • 早期截短APC变体(如Apc Min)与AXIN1和β-catenin相互作用有限,对TNKS阻断无反应。

临床怎么用

  • APC基因型可能作为结直肠癌患者接受TNKS抑制剂治疗的疗效预测标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The majority of colorectal cancers show hyperactivated WNT signaling due to inactivating mutations in the adenomatous polyposis coli (APC) tumor suppressor. Genetically restoring APC suppresses WNT and induces rapid and sustained tumor regression, implying that reengaging this endogenous tumor-suppressive mechanism may be an effective therapeutic strategy. Here, using new animal models, human cell lines, and ex vivo organoid cultures, we show that tankyrase (TNKS) inhibition can control WNT hyperactivation and provide long-term tumor control in vivo, but that effective responses are critically dependent on how APC is disrupted. Mutant APC proteins truncated within the mutation cluster region physically engage the destruction complex and suppress the WNT transcriptional program, while APC variants with early truncations (e.g., Apc Min) show limited interaction with AXIN1 and β-catenin, and do not respond to TNKS blockade. Together, this work shows that TNKS inhibition, like APC restoration, can reestablish endogenous control of WNT/β-catenin signaling, but that APC genotype is a crucial determinant of this response. SIGNIFICANCE: This study reveals how subtle changes to the mutations in a critical colorectal tumor suppressor, APC, influence the cellular response to a targeted therapy. It underscores how investigating the specific genetic alterations that occur in human cancer can identify important biological mechanisms of drug response and resistance.This article is highlighted in the In This Issue feature, p. 1325.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Schatoff EM, Goswami S, Zafra MP, et al. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition. Cancer Discov. 2019. PMID: 31337618. doi:10.1158/2159-8290.CD-19-0289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。